Download our whitepaper,

"Understanding Age-related Macular Degeneration (AMD): Epidemiology, Clinical Implications & Strategies for Clinical Trial Success"

iNGENuCRO_AMD

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for AMD Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for AMD.
  • Comprehensive Analysis of FDA-Approved AMD Drugs.
  • How Diagnostic Criteria for AMD Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in AMD Clinical Trials.
  • And additional insights to drive your trial's success.

Access your complimentary whitepaper today:

Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration (AMD) is a prevalent condition affecting the central part of the retina, known as the macula, which is responsible for sharp, straight-ahead vision.

The understanding of AMD has evolved significantly over the years. Initially, little was known about the disease's pathogenesis and treatment. However, advancements in medical research have led to better diagnostic techniques and therapeutic interventions. Historical perspectives show that the condition was once considered an unavoidable part of aging, but now, factors contributing to its development, such as genetics, environment, and lifestyle, are increasingly recognized.


AMD affects over

170M

people worldwide, with numbers projected to rise




Dry AMD accounts for approximately

85-90%

of AMD cases

 



10-15%

of dry AMD cases progress to wet AMD, which can lead to rapid vision loss if untreated

 

Our clinical team has over

120

years of combined clinical trial experience